Andra AP fonden Increases Position in Alnylam Pharmaceuticals, Inc. $ALNY

Andra AP fonden increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 134.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 48,540 shares of the biopharmaceutical company’s stock after acquiring an additional 27,840 shares during the quarter. Andra AP fonden’s holdings in Alnylam Pharmaceuticals were worth $19,302,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Colonial Trust Co SC boosted its position in shares of Alnylam Pharmaceuticals by 160.5% during the fourth quarter. Colonial Trust Co SC now owns 99 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 61 shares during the last quarter. Principal Securities Inc. boosted its position in shares of Alnylam Pharmaceuticals by 7.7% during the fourth quarter. Principal Securities Inc. now owns 2,626 shares of the biopharmaceutical company’s stock worth $1,044,000 after acquiring an additional 188 shares during the last quarter. Aviva PLC boosted its position in shares of Alnylam Pharmaceuticals by 7.2% during the fourth quarter. Aviva PLC now owns 110,662 shares of the biopharmaceutical company’s stock worth $44,005,000 after acquiring an additional 7,456 shares during the last quarter. ICICI Prudential Asset Management Co Ltd bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $843,000. Finally, UniSuper Management Pty Ltd boosted its position in shares of Alnylam Pharmaceuticals by 13.6% during the fourth quarter. UniSuper Management Pty Ltd now owns 2,500 shares of the biopharmaceutical company’s stock worth $994,000 after acquiring an additional 300 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ALNY shares. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Chardan Capital restated a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $289.39 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $283.10 and a 52 week high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The company has a fifty day simple moving average of $305.23 and a two-hundred day simple moving average of $344.11. The firm has a market capitalization of $38.64 billion, a P/E ratio of 79.07 and a beta of 0.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the business earned ($0.44) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 7,740 shares of company stock valued at $2,420,214. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.